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Background: Standard glucocorticoid therapy in congenital adrenal hyperplasia regularly fails to 
control androgen excess, causing glucocorticoid over-exposure and poor health outcomes. We 
investigated whether modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol 
secretion, could improve disease control. 
Methods: 6-month randomized phase III study, MR-HC versus standard glucocorticoid, followed by 
single-arm MR-HC extension study. Primary outcomes were change in 24-hour standard deviation 
score (SDS) of androgen precursor 17-hydroxyprogesterone (17OHP) for phase III, and efficacy, 
safety and tolerability of MR-HC for the extension study.  
Results: The phase III study recruited 122 adult CAH patients. While the study failed its primary 
outcome at 6 months, there was evidence of better biochemical control on MR-HC, with lower 
17OHP SDS at 4 (P=0.007) and 12 (P=0.019) weeks, and between 07:00h to 15:00h (P=0.044) at 6 
months. The percentage of patients with controlled 09:00h serum 17OHP (<1200 ng/dl) was 52% at 
baseline, at 6 months 91% for MR-HC and 71% for standard therapy (P=0.002), and 80% for MR-HC 
at 18 months extension. The median daily hydrocortisone dose was 25mg at baseline, at 6 months 
31mg for standard therapy and 30mg for MR-HC, and after 18 months 20mg MR-HC. Three adrenal 
crises occurred in phase III, none on MR-HC and 4 in extension study. MR-HC resulted in patient-
reported benefit including menses restoration in eight patients (one on standard therapy), and 3 
patient and 4 partner pregnancies (none on standard therapy). 
Conclusion: MR-HC improved biochemical disease control in adults with reduction in steroid dose 
over time and patient-reported benefit.  
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Classic congenital adrenal hyperplasia, due to 21-hydroxylase deficiency (21-OHD-CAH), is a genetic 
disorder of steroidogenesis affecting ~1:15,000 live births (1). Lack of 21-hydroxylase causes cortisol 
deficiency and a counter-regulatory increase in pituitary adrenocorticotropic hormone (ACTH) 
secretion, which drives overproduction of adrenal androgens, and adrenal hyperplasia. Patients with 
21-OHD-CAH have two major problems: adrenal insufficiency and androgen excess. Adrenal 
insufficiency causes life threatening adrenal crises (1-3), while androgen excess causes atypical 
genitalia in 46,XX neonates, promotes abnormal growth, short stature and precocious puberty, and 
in adulthood, virilization of women and infertility in both sexes (4). Treatment aims to replace 
cortisol, and, where necessary, aldosterone. Supra-physiologic doses of glucocorticoid are typically 
needed to suppress ACTH and adrenal androgens. Management involves balancing glucocorticoid 
doses to avoid both glucocorticoid deficiency, risking adrenal crisis, and iatrogenic glucocorticoid 
excess, leading to short stature, obesity, hypertension, osteoporosis and an adverse metabolic 
profile (1-3,5-7). Patients with 21-OHD-CAH have increased mortality (8,9), and poor health 
outcomes (10,11), as current therapy fails to control adrenal androgen excess resulting in 
glucocorticoid overtreatment (5,12). 
 Cortisol has a circadian rhythm with a nadir on going to sleep, increasing during early 
morning hours, peaking on waking, then decreasing through the day (13). In 21-OHD-CAH, absent 
cortisol overnight results in excess early morning ACTH which in turn drives excess generation of 
adrenal androgens. The adrenal androgen precursors, 17-hydroxyprogesterone (17OHP) and 
androstenedione are used for monitoring. Current glucocorticoids used in the treatment of 21-OHD-
CAH are immediate release preparations such as hydrocortisone, prednisolone, prednisone, and 
dexamethasone, which fail to mimic the early morning cortisol rise (10,11). There is consensus that 
hydrocortisone should be used in children to avoid risk of growth suppression with long-acting 
glucocorticoids (14); however, in adults, there is no agreement on which glucocorticoid to use. 
Patients often take glucocorticoids later in the evening to achieve biochemical control, when cortisol 
is normally low, resulting in  metabolically adverse consequences (15). Despite different treatment 
regimens, optimal biochemical control, defined as 17OHP below three times the upper limit of 
normal (<1200 ng/ml, 36 nmol/l) and androstenedione within the reference range, is only achieved 
in ~40% of patients (10,11).  
 Hydrocortisone infusions mimicking the cortisol circadian rhythm have demonstrated 
improved biochemical control of 21-OHD-CAH (16,17). A modified-release formulation of 




















rise of cortisol (18,19), and improved 21-OHD-CAH disease control in a phase II study (19). We now 
report findings from a phase III study of MR-HC versus standard glucocorticoid therapy followed by a 





Patients were recruited from 10 centers (7 countries) from February 2016 to January 2018. Patients 
had classic 21-OHD-CAH diagnosed in childhood, adequate mineralocorticoid replacement with renin 
less than 2 times the upper limit of normal, and were on stable glucocorticoid therapy over the 
preceding six months. Exclusion criteria included use of medication interfering with glucocorticoid 
metabolism, bilateral adrenalectomy and night shift work. The study protocols for the phase III 
extension study were approved by local Ethics/Institutional Review Boards and the Medicines and 
Healthcare Products Regulatory Agency (NCT03062280, Eudract 2015-005448-32). The trials were 
performed in accordance with the principles of the Declaration of Helsinki.  
 
Trial Design  
Patients, stratified by baseline glucocorticoid treatment (Table 1), were randomized by an 
Interactive Web Response System to receive MR-HC (Chronocort
®
 Diurnal Ltd. UK) or to 
continue on standard therapy and after 6 months were offered MR-HC in the extension study. 
MR-HC was prescribed as 5, 10 or 20 mg capsules and the initial dose was the 
hydrocortisone dose equivalent to their baseline therapy with approximately 
1
/3 of the daily 




of the daily dose taken at 23:00h. At 4 and 12 weeks, dose 
titrations were made for both treatment groups, using identical rules, following centralized 
advice by two independent physicians blinded to all data except 24-hour hormone profiles 
and an investigator-completed adrenal insufficiency checklist. The blinded titrators 
considered morning and/or evening dose adjustments of either MR-HC or standard 
glucocorticoid using 17OHP/androstenedione measurements from the 24-hour profile and 
adrenal insufficiency symptom questionnaire (Table 2) results using the following algorithm: 
 The 5 samples between 01:00 to 09:00hrs were considered to reflect glucocorticoid 




















 The 5 samples between 11:00 and 19:00hrs to reflect glucocorticoid given in the 
morning.   
 If 3 or more of these 5 samples were out of range, dose adjustments would be made, 
unless the adrenal insufficiency symptom questionnaire was in conflict with the 
biochemical findings.   
 If 17OHP and androstenedione were inconsistent then the androstenedione results were 
to take precedence.   
Target ranges for titration were the optimal range for 17OHP and reference range for 
androstenedione as follows: 
 17OHP 40-1200ng/dl (1.2 – 36.4 nmol/l) 
 androstenedione (males) 40-150 ng/dl (1.4 - 5.2nmol/L) 
 androstenedione (females) 30-200ng/dl (1.0 - 7.0 nmol/L) 
Local investigators and patients were aware of the trial-group assignment but were otherwise 
blinded. After 6 months, patients who had enrolled in the phase III, and the previous phase II 
studies were invited to enroll in the extension study. The initial dose of MR-HC was the 
hydrocortisone dose equivalent to their dose at time of enrollment in the extension study. 
Dose titration was performed by the local investigators according to hormone results and 
symptoms of over- or under-replacement. Hydrocortisone stress dosing and fludrocortisone 
dose adjustment occurred as medically indicated (20).   
 
Trial Procedures  
In the phase III study, 17OHP and androstenedione were measured at baseline, 4, 12, and 24 
weeks every 2 hours from 15:00hrs to 15:00hrs, and in the extension study, blood was drawn 
at 09:00h and 13:00h.  Hormones were measured by HPLC–tandem mass spectrometry (Q
2 
Solutions, USA). Additional assessments included; body composition, DEXA scanning, 
metabolic bloodwork (C-terminal cross-link telopeptide, fasting osteocalcin, highly sensitive 
C-reactive protein (hsCRP), fasting glucose, fasting insulin, HbA1c, plasma renin activity, 























The primary outcome in the phase III study was the change from baseline to 24 weeks in the mean 
of the 24-hour 17OHP standard deviation scores (SDS). Natural log transformation was performed to 
approximate a normal distribution. For each 2-hourly value of log 17OHP,  the number of standard 
deviations from the midpoint of the natural logarithm of the reference range (males 40-220ng/dl 
(1.2-6.7 nmol/L), females 40-285 ng/dl (1.2-8.6 nmol/L)) was calculated, unsigned to provide equal 
weight to values above or below the midpoint. Secondary outcomes included serum 
androstenedione, safety (specifically stress dosing and adrenal crises)(21), and changes in weight, 
body mass index (BMI), waist circumference, body composition and blood pressure (BP). Exploratory 
endpoints included the primary outcome at 4 and 12 weeks. Post hoc analyses included percentage 
of patients with good disease control defined as 09:00h for 17OHP <1200 ng/dl (<36 nmol/L) and for 
androstenedione below the reference range upper limit as previously defined (10,11); areas under 
the curve (AUC) of 17OHP and androstenedione; and 17OHP variability expressed as the ratio of 
arithmetic range of concentrations over 24-hours at 24 weeks to baseline. In the extension study, 
the primary endpoint was MR-HC safety assessed longitudinally using signs and symptoms of adrenal 
insufficiency or over-treatment; use of sick day rules; and adverse events including adrenal crises. 
The secondary endpoints included MR-HC long-term efficacy measurements such as daily dose of 
hydrocortisone and disease control assessed via 17OHP and androstenedione.  As patients had 




The trial was designed to have > 95% power, at a 2-sided alpha of 5%, to detect a difference 
between treatment groups in the primary outcome consistent with the phase II study results. The 
primary outcome was compared between treatment groups within an analysis of covariance 
(ANCOVA) linear model with pre-study treatment category and baseline mean SDS as covariates.  
The same model was used for secondary and exploratory analyses of SDS and the area under the 24-
hour profiles curve (AUC). Variability (amplitude) within a 24-hour hormone profile was defined as 
the maximum value divided by the minimum value. The change in the amplitude between baseline 
and 24 weeks, expressed as a ratio, was compared between treatment groups using a Wilcoxon test. 
The proportion of patients with good disease control at 24 weeks (09:00h 17OHP less than 1200 




















control at baseline. All P values are two-tailed and all confidence intervals (CIs) are 95% two-sided.   
Since all subjects participating in the extension trial received MR-HC there were no formal treatment 
comparisons, but summaries over time were produced for safety and efficacy parameters. 
 
Safety 
Adverse events were recorded including adverse events of special interest such as adrenal crisis. 
Events of therapeutic benefit such as restoration of menstruation have been recorded using the 
MedDRA term “Unexpected therapeutic benefit” as recommended by regulators.   
RESULTS 
Patients 
In the phase III study, 138 patients were screened, 122 randomized, 117 completed the study, and 
105 met criteria for efficacy analysis (Figure 1). Between 3 and 25 patients were recruited from each 
European center with 8 from the US center.  Overall, the two treatment groups were balanced 
(Table 1), but the number of patients with good baseline disease control was higher in the standard 
group. At baseline, 84% of patients were taking standard glucocorticoid after 18:00hrs, and 84% of 
patients were diagnosed as salt wasting (Table 1). Five patients (3 MR-HC, 2 standard) had 
experienced an adrenal crisis in the preceding year. In the extension study, 91 patients received at 
least one dose of MR-HC and 83 were participating at time of this data cut (Figure 1). Safety data are 
presented up to 2 years and biochemical up to 18 months.  Patients who chose not to participate in 
the extension study did so predominantly from one center because of logistical reasons (n=13). 
Withdrawals were primarily for practical reasons including desire for pregnancy. 
 
Biochemical Disease Control  
In phase III, both groups achieved better hormonal control at 24 weeks compared to baseline 
reflected by a negative change in the 17OHP SDS 24-hour profile, therefore the trial failed its 
primary outcome (P=0.55) (Table 3). There was no statistical difference between any of the groups 
and removing any of the groups from the analysis did not change the primary outcome. The change 
from baseline was greater in MR-HC group at 4 (P = 0.007) and 12 (P = 0.019) weeks. At 24 weeks, a 
greater reduction in the 17OHP SDS profile was observed in the MR-HC group compared to the 




















in both groups, with greater reduction in the MR-HC group (P = 0.025). At 24 weeks, compared to 
standard group, good disease control (17OHP <1200ng/dl at 09:00h) was achieved more often in the 
MR-HC group (90.6% vs. 71.2%, P = 0.002) and 17OHP variability (amplitude) over 24 hours was 
reduced in the MR-HC group (P < 0.001). At baseline the group randomised to continue on standard 
treatment were better controlled than the MR-HC group 32/52 (62%) vs 20/53 (38%) and after 24 
weeks 28/33 (85%) of those not in control at baseline were controlled in the MR-HC group and 
10/20 (50%) in the standard treatment group. The androstenedione SDS profile and change in AUC 
was similar to that for 17OHP. The pattern of biochemical control displayed in the 24-hour profiles 
differed between the two groups (Figure 2). At 24 weeks, the MR-HC group 24 hour profile flattened 
and normalized for both 17OHP (Figure 2A) and androstenedione (Figure 2B), while the pathological 
morning rise in adrenal androgen precursors persisted in the standard group (Figure 2C, 2D). Thus, a 
difference between the two groups at week 24 was observed during the morning hours, but not 
throughout the day (Figure 2E, 2F).  In the extension study, the number of patients in good disease 
control for 17OHP at 09:00h was 80% at 18 months versus 52% at baseline (Figure 2G, Table 1&3) 
and for androstenedione 96% versus 45% at baseline. In the phase III study it didn’t make a 
difference to the analysis whether good control was measured at either 0700h or 0900h so we used 
0900h in the extension study as this is when many clinics measure hormones. 
 
Daily glucocorticoid and mineralocorticoid dose  
At 24 weeks, the MR-HC group increased from a median dose of 25mg to 30mg and standard 
glucocorticoid from 25mg to 31mg hydrocortisone dose equivalent (Table 4). Overall and by type of 
glucocorticoid at baseline, the MR-HC and standard groups were receiving similar glucocorticoid 
doses, but more patients required up-titrations in the standard group (31 vs. 28) and more required 
down-titrations in MR-HC group (13 vs. 3). The dose of fludrocortisone was changed in 3 patients (2 
MR-HC and one Standard). In the extension study, patients were down-titrated and the median dose 
at 18 months was 20mg (Table 4). 
 
There was no statistical difference between subjects on the different standard treatment regimens 
at baseline and removing any of the groups from the analysis did not change the primary outcome. 
In the prednisolone / prednisone at baseline patient group, the hydrocortisone dose on MR-HC fell 
from a median of 30mg at baseline to 27.5mg at 24 weeks and for those that continued on 




















relatively few patients on dexamethasone at baseline (n=10) and they were split into those 
continuing dexamethasone (n=5) and those who transferred to MR-HC (n=5). For the patients who 
were on dexamethasone at baseline the median dose in hydrocortisone equivalents of 
dexamethasone and MR-HC did not change from baseline to 24 weeks. 
 
Secondary outcomes of interest  
No differences between the two treatment groups were seen for fat mass, lean mass or bone 
mineral density by DEXA; bone markers (serum C-terminal telopeptide and fasting osteocalcin); 
laboratory assessments of interest including high-sensitivity C-reactive protein, fasting glucose, 
fasting insulin, homeostatic model assessment of insulin resistance, glycated hemoglobin, total 
testosterone, and plasma renin activity (Table 5).   No significant changes in QoL were seen although 
responses for the majority of domains improved (Table 6).  
Safety 
In phase III study, no patients experienced adrenal crises in the MR-HC group compared with three 
(4.9%) in the standard group. A total of 299 adverse events (15 of therapeutic benefit) were 
reported by 96.7% of patients in the MR-HC group and 224 adverse events (1 of therapeutic benefit) 
were reported by 78.7% of patients in the standard group. No serious adverse event was considered 
causally related to study intervention. Glucocorticoid stress dosing was reported by 26 patients 
(42.6%) in the MR-HC group and 36 patients (59.0%) in the standard group. Unexpected events 
considered to be of therapeutic benefit included resumption of regular menses in 5 patients (4 MR-
HC, 1 standard), partner pregnancies of two patients in the MR-HC group with full-term deliveries; 
one of these patients had a history of testicular adrenal rest tissue with documented sperm count 
improvement (<0.1 million/ml prior to MR-HC and 10.3 million/ml during MR-HC treatment).  
 
In the extension study there were 4 patients with adrenal crisis.  A total of 780 AEs (29 of 
therapeutic benefit) were reported by 87 participants (95.6%). SAEs were reported for 14 
participants (15.4%), of which one was considered related to MR-HC (hypokalemia). Glucocorticoid 
stress dosing was reported for 72 participants (79.1%). The most common 18 patients (19.8%) 
reported events considered to be of therapeutic benefit were feeling more alert (11 patients), and 




















during the study and successfully delivered.  Three patients became pregnant on MR-HC, one 





This is the first randomized controlled trial of glucocorticoid treatment in patients with 21-OHD-CAH.  
Patients who received MR-HC had superior hormonal control during the morning and early 
afternoon compared to those receiving standard therapy and this was sustained over 18 months 
follow up. Morning hormonal control is important in 21-OHD-CAH as failure to control the overnight 
rise in adrenal androgens results in excess glucocorticoid exposure and poor health outcomes (5). 
The trial failed its primary endpoint because the difference between the two groups in the morning 
did not translate into a difference over 24 hours at 24 weeks. The primary outcome was based on a 
phase II trial (19), however the analysis was unhelpful in the phase III randomized trial as the SDS 
analysis overemphasized scores below the midpoint of the reference range and the logarithmic 
transformation and use of a mean score over 24 hours obscured the impact of MR-HC in the 
morning and early afternoon. The raw data showed significant improvement of the clinically relevant 
endpoint of morning biochemical control, with reduced AUC and 17OHP amplitude in patients 
receiving MR-HC. The improvement in biochemical control was maintained at 18 months, with 80% 
displaying good control for 17OHP and 96% for androstenedione versus 52 and 45% at baseline 
despite reduction of the hydrocortisone dose by 33%, to doses regularly used for adrenal 
replacement therapy.  
 MR-HC replicates the physiological overnight rise in cortisol thereby preventing ACTH driven 
excess production of adrenal androgens (19). MR-HC given twice daily replicates both the early 
morning rise in cortisol as well as daytime cortisol levels (22). There is some evidence that cortisol 
clearance may vary over 24 hours, possibly related to a circadian rhythm in cortisol-binding protein; 
however, the amplitude of this variation is small and does not appear clinically significant (23). 
Biochemical control was better on MR-HC compared to standard glucocorticoid at 4 weeks (i.e. prior 
to dose titration) when patients were receiving MR-HC at an equivalent daily dose to baseline 
treatment. At 24 weeks, following dose titration, morning control was better on MR-HC than 
standard glucocorticoid, 91% in control versus 71%, respectively, with little fluctuation in 17OHP and 




















These findings are important as it is the high excursions in 17OHP that drive production of 
androstenedione and androgens that impact growth, puberty and fertility.   
 Immediate-release hydrocortisone is the recommended first line therapy in 21-OHD-CAH; 
prednisolone and dexamethasone are introduced when biochemical control cannot be achieved, but 
are associated with higher rates of adverse outcomes (15,24,25). Higher bedtime doses (reverse 
circadian regimen) are commonly used in an attempt to improve androgen control (11,26,27), 84% 
at baseline in this study; however, evening glucocorticoid administration has potential for adverse 
metabolic actions (28), and insomnia. The median hydrocortisone dose at 24 weeks was 15.8 and 
17.0 mg/m2/day for MR-HC and standard group, respectively, similar doses to those reported in 
cohort studies (15-18 mg/m2/day) where biochemical control was worse than in this trial 
(10,11,29,30).  In the extension study, with local clinicians performing dose titrations, biochemical 
control was maintained at a reduced daily dose of 20mg consistent with that recommended for 
replacement in adrenal insufficiency; 15-25mg daily (31). Upon study entry the patients had their 
therapy optimized for 6 months, and yet were able to have a sustained dose reduction in the 
extension study. Optimal control of adrenal androgens is required for fertility in men and women 
with 21-OHD-CAH (32-34). Our findings demonstrate clinical value for improved morning hormonal 
control, with women restarting menstruation, improved sperm quality in a patient with testicular 
adrenal rest tissue, and four partner and three patient pregnancies on MR-HC.  
There are few published data on the circadian variation of 17OHP in healthy individuals but, 
what there is, demonstrates that in the normal individual 17OHP displays minor circadian variability 
within the reference range and varies by the phase of the menstrual cycle in females (35,36). The 
reference range for 17OHP at the Mayo is <285 ng/dL during the luteal phase which is the highest 
level seen in healthy subjects. Clinicians have recognised that in patients with CAH receiving 
standard therapy it is not possible to control 17OHP in the morning even when raising the dose of 
glucocorticoid. This is shown in the current study in patients on standard treatment where their 
glucocorticoid dose was increased. To avoid over treatment, guidelines have suggested to not 
suppress the 17OHP in to the reference range and two observational cohort studies of CAH defined 
an optimal range of 17OHP to be < 1200ng/dl which approximates to three times the upper limit of 
the normal range (11,37). Our phase III study shows that by treating with MR-HC, which provides a 
physiological rise in cortisol levels overnight, it is now possible to control the overnight rise in 17OHP 
such that a relatively flat 17OHP profile over 24 hours is achieved, similar to that seen in healthy 
subjects. In the phase III study, we found that MR-HC at 30mg a day controls many patients in to the 




















provided and where control is generally < 50% (10,11,29,30).  When the dose of MR-HC was reduced 
in the extension study to adrenal replacement levels, median dose 20mg, the 17OHP remained in 
the optimal range in 80% of patients. This median dose is 20 to 40% less (5 to 10mg a day less) than 
that reported in the cohort studies (10,11,29,30). The “optimal” 17OHP level could be debated and 
practices vary among clinicians; however, there is agreement that lower glucocorticoid doses are 
beneficial and this was achieved in the extension study with female patients reporting 
improvements in menstrual regularity and improvement in fertility in both sexes. 
 The evidence that an adrenal replacement dose of hydrocortisone has better health 
outcomes than the higher doses more commonly used in CAH, comes from the literature examining 
hydrocortisone replacement therapy in adrenal insufficiency. In a large retrospective studies of 
patients on glucocorticoids a hydrocortisone equivalent dose > 20mg / day was associated with an 
unfavourable metabolic profile (38), and a daily dose of HC greater that 25mg / day was associated 
with increased mortality (39). Similarly higher replacement doses of hydrocortisone have been 
associated with lower quality of life (QoL) in patients with adrenal insufficiency (40), and lower 
psychological wellbeing (41).  In a large longitudinal historical cohort study in paediatric patients the 
dose of hydrocortisone in patients with CAH was negatively associated with final height with each 
1mg/m2/day of hydrocortisone equating to a loss of 0.37cm height (42). 
Currently there is no consensus on monitoring glucocorticoid therapy in CAH (10). Clinicians 
measure biomarkers both before and after dosing (43), and aim for 17OHP levels above the 
reference range and androstenedione within the reference range for good control, with normal 
17OHP indicating over-treatment and high androstenedione indicating under-treatment (14,24). In 
21-OHD-CAH, the physiological pathway to androstenedione biosynthesis from 17-
hydroxypregenolone via DHEA is downregulated (43,44), and androstenedione biosynthesis 
primarily occurs through conversion of excess 17OHP. With MR-HC treatment, we observed near 
normalization of 17OHP and concurrently low androstenedione, despite a median daily MR-HC dose 
of 20mg, suggesting that the low androstenedione is not explained by glucocorticoid-mediated 
suppression. Thus, you can’t keep down titrating the glucocorticoid dose based on a low A4 as you 
will go below adrenal replacement doses and risk adrenal insufficiency. The mode of action of MR-
HC flattens the 24 hour 17OHP profile, similar to that seen in healthy subjects, and provides the 
rationale for a monitoring and titration scheme whereby the morning 17OHP reflects the evening 
dose and the afternoon 17OHP the morning dose of MR-HC. Thus, in the extension study, patients 
have been titrated using a sample measured at 0900h and 1300h which are times suitable for the 




















assays for saliva and blood spot are available. MR-HC provides a potential simplified paradigm for 
the treatment and monitoring of CAH with dosing at bedtime and waking, and hormonal 
measurements at 0900h to judge the nighttime dose and around midday to judge the morning dose.  
 The lack of significant differences in clinical and patient reported outcomes between the two 
groups in the phase III study reflects the short duration of the study and similar daily glucocorticoid 
doses. QoL has been shown to improve when using a pump to deliver subcutaneous diurnal 
hydrocortisone infusion to 21-OHD-CAH patients with poor control and QoL at baseline (17); 
however, QoL in 21-OHD-CAH has variably been reported as either impaired or normal (45). Our 
patients were a diverse population at baseline with similar QoL to the general population, which 
would make demonstrating improvement difficult.   
 Over a third of patients had an infection during the study consistent with the observation 
that patients with adrenal insufficiency have higher infection rates (46), and emphasizes the 
importance of teaching patients sick day rules. Mortality in patients with 21-OHD-CAH is increased 
and adrenal crisis is responsible for up to 42% of excess deaths (8,9). The incidence of adrenal crisis 
in patients with adrenal insufficiency is estimated to be 5–10 adrenal crises/100 patient years with a 
mortality rate of 0.5/100 patient years (20,21,47-49). Five of 122 patients had an adrenal crisis in the 
year before the study (3 randomized to MR-HC), and during the randomized study, 3 patients in the 
standard group had an adrenal crisis but none in the MR-HC group. In the extension study, 4 patients 
had an adrenal crisis with a frequency of 6.2 crises per 100 treatment years, similar to population 
estimates (20,49,50), and providing confi ence that the safety profile of MR-HC does not differ from 
that of immediate-release hydrocortisone.  
 A strength of our phase III study was the international multicenter randomized design 
enabling us to study a large cohort in a rare disease; the extension study provided data on up to 2 
years of treatment with MR-HC, a sound basis for efficacy and safety assessment.  The limitations of 
the phase III study include; the open label design (mitigated by the blinded dose titration), and the 
complexity of the protocol and statistical analysis. Blinding was considered impractical due to 
multiple dosing regimens and the difficulties replicating the bitterness of hydrocortisone in a 
placebo.  It was challenging to admit patients for a 24-hour profile, which may have restricted 
recruitment and created a selection bias for better controlled patients. The intensive monitoring and 
more aggressive dose up-titration than usually performed in clinical practice may explain the 
improved control in the standard group compared to previous observational studies of 21-OHD-
CAH,(10,11) and the extension study demonstrated that MR-HC dose reduction could be achieved 




















 In conclusion, we found that MR-HC improved morning and early afternoon biochemical 
control of 21-OHD-CAH over standard glucocorticoid therapy. This control was sustained for 18 
months on hydrocortisone doses recommended for adrenal replacement therapy and lower than 
doses normally used in 21-OHD-CAH. MR-HC provides a well-tolerated and practical twice-daily 
treatment regimen for 21-OHD-CAH. 
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Figure 1: Screening, Randomization Treatment and Follow-up of the Patients. 
The safety population included all randomly assigned patients who received at least one dose of trial 
treatment. *Patients could have more than one reason for study exclusion and withdrawn patients 
are included in patients excluded. 
 
Figure 2: 24 Hour Endocrine Profiles for 17-Hydroxyprogesterone (17OHP) and Androstenedione at 
Week 24 versus Baseline (geometric mean ± 95% CIs, patients meeting the criteria for the efficacy 
analysis) and 09:00hrs 17OHP during the extension study.  
At week 24, the 17OHP 24-hour profile for patients receiving MR-HC was flat, and the morning rise in 
17OHP observed at baseline was no longer present (Panel A). Similar results were observed for 
androstenedione (Panel B). Patients in the standard glucocorticoid group had improvement in 
hormonal control with glucocorticoid dose adjustments according to the protocol, but the pattern of 
hormone secretion did not change: the 17OHP (Panel C) and androstenedione (Panel D) profiles 
continued to display a morning increase. At week 24, the MR-HC vs. standard groups differed during 
the morning hours but not throughout the 24 hours for 17OHP (Panel E) and androstenedione (Panel 
F). During the extension study, the geometric mean 09:00h 17OHP fell from baseline into the 
optimal range and remained there despite a reduction in MR-HC daily dose (Panel G). 
 
Data Availability: Datasets generated during and analyzed during the current study are not publicly 



























1. Merke DP, Auchus RJ. Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. N 
Engl J Med 2020; 383:1248-1261 
2. Cutler GB, Jr., Laue L. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N 
Engl J Med 1990; 323:1806-1813 
3. Rushworth RL, Torpy DJ, Falhammar H. Adrenal Crisis. N Engl J Med 2019; 381:852-861 
4. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005; 365:2125-2136 
5. Han TS, Walker BR, Arlt W, Ross RJ. Treatment and health outcomes in adults with 
congenital adrenal hyperplasia. Nat Rev Endocrinol 2014; 10:115-124 
6. Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, Prokop LJ, Bancos I, Speiser PW, Murad MH. 
Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic 
Review and Meta-Analysis. J Clin Endocrinol Metab 2018; 103:4097-4103 
7. Speiser PW, White PC. Congenital adrenal hyperplasia. N Engl J Med 2003; 349:776-788 
8. Jenkins-Jones S, Parviainen L, Porter J, Withe M, Whitaker MJ, Holden SE, Morgan CL, Currie 
CJ, Ross RJM. Poor compliance and increased mortality, depression and healthcare costs in 
patients with congenital adrenal hyperplasia. Eur J Endocrinol 2018; 178:309-320 
9. Falhammar H, Frisen L, Norrby C, Hirschberg AL, Almqvist C, Nordenskjold A, Nordenstrom A. 
Increased mortality in patients with congenital adrenal hyperplasia due to 21-hydroxylase 
deficiency. J Clin Endocrinol Metab 2014; 99:E2715-2721 
10. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, 
Rees DA, Stimson RH, Walker BR, Connell JM, Ross RJ, United Kingdom Congenital Adrenal 
Hyperplasia Adult Study E. Health status of adults with congenital adrenal hyperplasia: a 
cohort study of 203 patients. J Clin Endocrinol Metab 2010; 95:5110-5121 
11. Finkielstain GP, Kim MS, Sinaii N, Nishitani M, Van Ryzin C, Hill SC, Reynolds JC, Hanna RM, 
Merke DP. Clinical characteristics of a cohort of 244 patients with congenital adrenal 
hyperplasia. The Journal of clinical endocrinology and metabolism 2012; 97:4429-4438 
12. Cutler GB. Treatment of congenital adrenal hyperplasia. Journal of Clinical Endocrinology & 
Metabolism 1996; 81:3185-3186 
13. Debono M, Ghobadi C, Rostami-Hodjegan A, Huatan H, Campbell MJ, Newell-Price J, Darzy K, 
Merke DP, Arlt W, Ross RJ. Modified-release hydrocortisone to provide circadian cortisol 
profiles. The Journal of clinical endocrinology and metabolism 2009; 94:1548-1554 
14. Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller 
WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia Due to Steroid 21-
Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol 
Metab 2018; 103:4043-4088 
15. Whittle E, Falhammar H. Glucocorticoid Regimens in the Treatment of Congenital Adrenal 
Hyperplasia: A Systematic Review and Meta-Analysis. J Endocr Soc 2019; 3:1227-1245 
16. Merza Z, Rostami-Hodjegan A, Memmott A, Doane A, Ibbotson V, Newell-Price J, Tucker GT, 
Ross RJ. Circadian hydrocortisone infusions in patients with adrenal insufficiency and 




















17. Nella AA, Mallappa A, Perritt AF, Gounden V, Kumar P, Sinaii N, Daley LA, Ling A, Liu CY, 
Soldin SJ, Merke DP. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion 
in Adults With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2016; 101:4690-4698 
18. Whitaker MJ, Debono M, Huatan H, Merke DP, Arlt W, Ross RJ. An oral multiparticulate, 
modified-release, hydrocortisone replacement therapy that provides physiological cortisol 
exposure. Clin Endocrinol (Oxf) 2014; 80:554-561 
19. Mallappa A, Sinaii N, Kumar P, Whitaker MJ, Daley LA, Digweed D, Eckland DJ, Van Ryzin C, 
Nieman LK, Arlt W, Ross RJ, Merke DP. A phase 2 study of Chronocort, a modified-release 
formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal 
hyperplasia. J Clin Endocrinol Metab 2015; 100:1137-1145 
20. El-Maouche D, Hargreaves CJ, Sinaii N, Mallappa A, Veeraraghavan P, Merke DP. 
Longitudinal assessment of illnesses, stress dosing and illness sequelae in patients with 
congenital adrenal hyperplasia. J Clin Endocrinol Metab 2018;  
21. Allolio B. Extensive expertise in endocrinology. Adrenal crisis. Eur J Endocrinol 2015; 
172:R115-124 
22. Porter J, Blair J, Ross RJ. Is physiological glucocorticoid replacement important in children? 
Arch Dis Child 2017; 102:199-205 
23. Melin J, Hartung N, Parra-Guillen ZP, Whitaker MJ, Ross RJ, Kloft C. The circadian rhythm of 
corticosteroid-binding globulin has little impact on cortisol exposure after hydrocortisone 
dosing. Clin Endocrinol (Oxf) 2019; 91:33-40 
24. Auchus RJ, Arlt W. Approach to the patient: the adult with congenital adrenal hyperplasia. J 
Clin Endocrinol Metab 2013; 98:2645-2655 
25. Paizoni L, Auer MK, Schmidt H, Hubner A, Bidlingmaier M, Reisch N. Effect of androgen 
excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital 
adrenal hyperplasia due to 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 2019; 
197:105540 
26. Auchus RJ. Management of the adult with congenital adrenal hyperplasia. Int J Pediatr 
Endocrinol 2010; 2010:614107 
27. Pijnenburg-Kleizen KJ, Thomas CMG, Otten BJ, Roeleveld N, Claahsen-van der Grinten HL. 
Long-term follow-up of children with classic congenital adrenal hyperplasia: suggestions for 
age dependent treatment in childhood and puberty. J Pediatr Endocrinol Metab 2019; 
32:1055-1063 
28. Plat L, Leproult R, L'Hermite-Baleriaux M, Fery F, Mockel J, Polonsky KS, Van Cauter E. 
Metabolic effects of short-term elevations of plasma cortisol are more pronounced in the 
evening than in the morning. J Clin Endocrinol Metab 1999; 84:3082-3092 
29. Chakhtoura Z, Bachelot A, Samara-Boustani D, Ruiz JC, Donadille B, Dulon J, Christin-Maitre 
S, Bouvattier C, Raux-Demay MC, Bouchard P, Carel JC, Leger J, Kuttenn F, Polak M, Touraine 
P. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 
21-hydroxylase deficiency. European journal of endocrinology / European Federation of 
Endocrine Societies 2008; 158:879-887 
30. Schnaider-Rezek GS, Lemos-Marini SH, Baptista MT, Guerra-Junior G, Morcillo AM, Mello 
MP, Oliveira LC, D'Souza-Li L. Metabolic evaluation of young women with congenital adrenal 
hyperplasia. Arquivos Brasileiros de Endocrinologia e Metabologia 2011; 55:646-652 
31. Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, Hammer GD, Husebye ES, Merke 
DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary Adrenal 
Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 
101:364-389 
32. Merke DP. Approach to the adult with congenital adrenal hyperplasia due to 21-hydroxylase 




















33. Casteras A, De Silva P, Rumsby G, Conway GS. Reassessing fecundity in women with classical 
congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin 
Endocrinol (Oxf) 2009; 70:833-837 
34. Bouvattier C, Esterle L, Renoult-Pierre P, de la Perriere AB, Illouz F, Kerlan V, Pascal-Vigneron 
V, Drui D, Christin-Maitre S, Galland F, Brue T, Reznik Y, Schillo F, Pinsard D, Piguel X, 
Chabrier G, Decoudier B, Emy P, Tauveron I, Raffin-Sanson ML, Bertherat J, Kuhn JM, Caron 
P, Cartigny M, Chabre O, Dewailly D, Morel Y, Touraine P, Tardy-Guidollet V, Young J. Clinical 
Outcome, Hormonal Status, Gonadotrope Axis, and Testicular Function in 219 Adult Men 
Born With Classic 21-Hydroxylase Deficiency. A French National Survey. J Clin Endocrinol 
Metab 2015; 100:2303-2313 
35. Ghizzoni L, Bernasconi S, Virdis R, Vottero A, Ziveri M, Volta C, Iughetti L, Giovannelli G. 
Dynamics of 24-hour pulsatile cortisol, 17-hydroxyprogesterone, and androstenedione 
release in prepubertal patients with nonclassic 21-hydroxylase deficiency and normal 
prepubertal children. Metabolism 1994; 43:372-377 
36. Fanelli F, Gambineri A, Belluomo I, Repaci A, Di Lallo VD, Di Dalmazi G, Mezzullo M, Prontera 
O, Cuomo G, Zanotti L, Paccapelo A, Morselli-Labate AM, Pagotto U, Pasquali R. Androgen 
profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy 
normal-weight ovulatory and anovulatory late adolescent and young women. J Clin 
Endocrinol Metab 2013; 98:3058-3067 
37. Arlt W, Willis DS, Wild SH, Krone N, Doherty EJ, Hahner S, Han TS, Carroll PV, Conway GS, 
Rees DA, Stimson RH, Walker BR, Connell JMC, Ross RJ, Adrenal UKC. Health Status of Adults 
with Congenital Adrenal Hyperplasia: A Cohort Study of 203 Patients. Journal of Clinical 
Endocrinology & Metabolism 2010; 95:5110-5121 
38. Filipsson H, Monson JP, Koltowska-Haggstrom M, Mattsson A, Johannsson G. The impact of 
glucocorticoid replacement regimens on metabolic outcome and comorbidity in 
hypopituitary patients. J Clin Endocrinol Metab 2006; 91:3954-3961 
39. Sherlock M, Reulen RC, Alonso AA, Ayuk J, Clayton RN, Sheppard MC, Hawkins MM, Bates 
AS, Stewart PM. ACTH deficiency, higher doses of hydrocortisone replacement, and 
radiotherapy are independent predictors of mortality in patients with acromegaly. J Clin 
Endocrinol Metab 2009; 94:4216-4223 
40. Bleicken B, Hahner S, Loeffler M, Ventz M, Decker O, Allolio B, Quinkler M. Influence of 
hydrocortisone dosage scheme on health-related quality of life in patients with adrenal 
insufficiency. Clin Endocrinol (Oxf) 2010; 72:297-304 
41. Falhammar H, Butwicka A, Landen M, Lichtenstein P, Nordenskjold A, Nordenstrom A, Frisen 
L. Increased psychiatric morbidity in men with congenital adrenal hyperplasia due to 21-
hydroxylase deficiency. J Clin Endocrinol Metab 2014; 99:E554-560 
42. Sarafoglou K, Addo OY, Turcotte L, Otten N, Wickremasinghe A, Pittock S, Kyllo J, Lteif AN, 
Himes JH, Miller BS. Impact of hydrocortisone on adult height in congenital adrenal 
hyperplasia-the Minnesota cohort. The Journal of pediatrics 2014; 164:1141-1146 e1141 
43. Debono M, Mallappa A, Gounden V, Nella AA, Harrison RF, Crutchfield CA, Backlund PS, 
Soldin SJ, Ross RJ, Merke DP. Hormonal circadian rhythms in patients with congenital 
adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers. Eur 
J Endocrinol 2015; 173:727-737 
44. Storbeck KH, Schiffer L, Baranowski ES, Chortis V, Prete A, Barnard L, Gilligan LC, Taylor AE, 
Idkowiak J, Arlt W, Shackleton CHL. Steroid Metabolome Analysis in Disorders of Adrenal 
Steroid Biosynthesis and Metabolism. Endocr Rev 2019; 40:1605-1625 
45. Han TS, Krone N, Willis DS, Conway GS, Hahner S, Rees DA, Stimson RH, Walker BR, Arlt W, 
Ross RJ, United Kingdom Congenital adrenal Hyperplasia Adult Study E. Quality of life in 
adults with congenital adrenal hyperplasia relates to glucocorticoid treatment, adiposity and 
insulin resistance: United Kingdom Congenital adrenal Hyperplasia Adult Study Executive 




















46. Tresoldi AS, Sumilo D, Perrins M, Toulis KA, Prete A, Reddy N, Wass JAH, Arlt W, 
Nirantharakumar K. Increased Infection Risk in Addison's Disease and Congenital Adrenal 
Hyperplasia. J Clin Endocrinol Metab 2020; 105 
47. Rushworth RL, Torpy DJ, Stratakis CA, Falhammar H. Adrenal Crises in Children: Perspectives 
and Research Directions. Horm Res Paediatr 2018; 89:341-351 
48. Eyal O, Levin Y, Oren A, Zung A, Rachmiel M, Landau Z, Schachter-Davidov A, Segev-Becker A, 
Weintrob N. Adrenal crises in children with adrenal insufficiency: epidemiology and risk 
factors. Eur J Pediatr 2019; 178:731-738 
49. Reisch N, Willige M, Kohn D, Schwarz HP, Allolio B, Reincke M, Quinkler M, Hahner S, 
Beuschlein F. Frequency and causes of adrenal crises over lifetime in patients with 21-
hydroxylase deficiency. European journal of endocrinology / European Federation of 
Endocrine Societies 2012;  
50. El-Maouche D, Hargreaves CJ, Sinaii N, Mallappa A, Veeraraghavan P, Merke DP. 
Longitudinal Assessment of Illnesses, Stress Dosing, and Illness Sequelae in Patients With 






























Number 61 61 91 
Age yrs - median (range)  35 (19-61) 40 (19-68) 35 (20- 67) 
Female sex - no. (%) 42 (68.9) 36 (59) 62 (68.1) 
Salt-wasting – no. (%) 49 (80) 51 (84) 77(85) 
BMI (kg/m
2
)  median (range) 27.8 (18.0-43.7) 27.0 (19.7-36.8) 28.3 (18.0, 43.7) 
Fludrocortisone use - no. (%) 52 (85) 52 (85) 77 (85) 
Fludrocortisone mcg/day, median 
(range)  
100 (25-400) 100 (25-400) 100 (25-500) 
Good disease control 
¥
 *  no. (%) 20 (37.7) 32 (61.5) 52 (50.0) 
  
Pre-study Glucocorticoid treatment   
Hydrocortisone - no. (%) 36 (59.0)  39 (63.9)  - 
Prednisolone - no. (%) 21 (34.4)  22 (36.1)  - 
Dexamethasone - no. (%) 5 (8.2)  5 (8.2)  - 
Prednisone - no. (%) 3 (4.9)  2 (3.3)  - 
¥Good disease control defined as 09:00h 17OHP <1200 ng/dl. 

























Table 2: Adrenal Insufficiency Checklist 
This questionnaire should be used to determine if symptoms of under- or over-replacement of 
glucocorticoids have occurred in the preceding 4 weeks.  
 
Date of assessment (mm/dd/yyyy): 
Please ask subject: Have you experienced any of the following symptoms more than once per week 









If Yes, do you believe this to be 
related to under or over 
replacement of glucocorticoid? 









Sudden weight loss     
Sudden weight gain     
Lack of appetite     
Nausea     
Vomiting     
Headache     
Blurred vision     
Fatigue     
Weakness     
Dizziness     
Lightheadedness     
Syncope (sudden loss 
of consciousness) 
    
Sleeping difficulties     
Increased acne     
Other     






















Table 3. Study Outcomes and Disease Relevant Clinical Events *  
 MR-HC  Group Standard Group Comparison between groups 
Biochemical Outcomes from Phase III (N=53) (N=52) Treatment Effect
#




Baseline natural log 17OHP SDS profile  1.25 ± 0.73 1.03 ± 0.82  
Change from baseline in natural log 17OHP SDS profile    
       24 hour profile at 4 weeks -0.37 ± 0.63 -0.07 ± 0.42 -0.26 [-0.46, -0.07], P=0.007 
         24 hour profile at 12 weeks -0.52 ± 0.85 -0.10 ± 0.67 -0.30  [-0.54, -0.05], P=0.019 
Primary endpoint: 24 hour profile at 24 weeks -0.40 ± 0.85 -0.17 ± 0.78 -0.07 [-0.30, 0.16], P=0.55 
07:00h – 15:00h  profile at 24 weeks -0.69 ± 0.96 -0.21 ±0.79 -0.29 [-0.56, -0.01], P=0.044  
    
Baseline natural log 17OHP 24-hour AUC  65.2 ± 38.5 54.0 ± 39.2  
Change from baseline in natural log 17OHP 24-hour AUC     
       24 hour profile at 4 weeks -23.9 ± 27.7 -6.1 ± 19.3 -16.6 [-25.5, -7.8], P<0.001 
         24 hour profile at 12 weeks -35.5 ± 35.3 -13.5 ± 28.5 -17.8 [-29.0, -6.6], P=0.002 
24 hour profile at 24 weeks -37.7 ± 42.6 -17.8 ± 29.0 -13.8 [-25.8,-1.8], P=0.025  
    
Amplitude ratio of 17OHP
¶
 : median [95% non-parametric CI]  0.36 [0.24, 0.65] 0.92 [0.77, 1.37] 0.38 [0.24, 0.61], P<0.001 
    
Baseline natural log Androstenedione 24-hour AUC  21.4 ± 30.4 13.9 ± 32.2  
Change from baseline in natural log Androstenedione 24-hour 
AUC 
   
       24 hour profile at 4 weeks -12.5 ± 22.2 -3.1 ± 11.3 -8.9 [-15.6, -2.1], P=0.011 
         24 hour profile at 12 weeks -20.6 ± 23.8 -8.0 ± 15.1 -10.9 [-18.3, -3.5], P=0.004 
24 hour profile at 24 weeks -22.9 ± 26.9 -9.3 ± 20.4 -10.5 [-18.7, -2.3], P=0.013 
    
Disease Relevant Clinical Events Phase III Study  (N=61) (N=61)  
Adrenal Crises, n of patients(%) 0 (0) 3 (5.8) N/A 
Stress dosing, n of patients (%) 26 (49.1) 36 (69.2) N/A 
Restoration of menses, n of patients (%) 4 (7.5) 1 (1.9) N/A 
Partner pregnancy (%) 2 (3.8) 0 (0) N/A 
    
Biochemical Outcomes from Extension Study (N=50)   
Good Disease control (17OHP) at 18 months, n of patients (%) 40 (80.0) - N/A 



















    
Disease Relevant Clinical Events Phase III Study (N=91)   
Adrenal Crises, n of patients (%) 4 (4.4) - N/A 
Stress dosing, n of patients (%) 72 (79.1) - N/A 
Restoration of menses, n of patients 4 (4.4) - N/A 
Patient pregnancy 2 (2.2) - N/A 
Partner pregnancy 1 (1.1) - N/A 
*Plus-minus values are means ± SD. CI denotes confidence interval. 
#Treatment effect is defined as least-squares mean difference (MR-HC minus Standard GC) for SDS profiles and 24-hour AUC adjusted for 
baseline value and pre-baseline therapy; as the ratio MR-HC to Standard GC for amplitude ratio; and as the odds ratio MR-HC versus Standard 
GC for good disease control adjusted for baseline disease control status. 
$Confidence intervals and P-values are obtained from an ANCOVA model for SDS profiles and 24-hour AUC, by the Hodges-Lehmann and 
Wilcoxon methods respectively for amplitude ratio, and from a logistic model for good disease control. 
¶ Amplitude is defined as the maximum divided by the minimum over the 24-hour assessment period. The ratio is the amplitude at 24 weeks 
divided by the amplitude at baseline. 
¥Good disease control defined as 09:00h 17OHP <1200 ng/dL 



























 Baseline 24 weeks Baseline 24 weeks 
All (hydrocortisone dose 
equivalents)** 
    
Median daily dose (mg) 25.0 30.0 25.0 31.3 
Range 15-50 10-65 12.5-80 12.5-80 
Median dose/BSA (mg/m2/day) 13.6 15.8 14.4 17.0 
On hydrocortisone at baseline     
Median daily dose (mg) 20.0 25.0 23.75 25.0 
Range 12.5-40 10-65 12.5-35 15-55 
Median dose/BSA (mg/m2/day) 12.0 15.1 12.3 14.5 
On prednis(ol)one at baseline     
Median daily dose (mg) 30 27.5 26.6 32.8 
Median dose/BSA (mg/m2/day) 16.7 16.5 15.7 18.5 
Range 12.5-50 15-50 12.5-50 12.5-50 
On dexamethasone at baseline     
Median daily dose (mg) 30 30 40 40 
Range 29.6-38 30-45 20-80 33.5-80 
Median dose/BSA (mg/m2/day) 17.3 17.3 17.5 20.6 
MR-HC Safety Extension Study 


















Median Daily Dose 
(mg) MR-HC 
30 26.0 25.0 20.3 20.1 20.0 




15.8 15.0 13.5 12.5 11.7 11.1 
Number of 
patients with data 
available 
91 91 88 87 74 50 
BSA, body surface area 
* Standard Glucocorticoid Group are patients who continued on their conventional pre-study 
glucocorticoid treatment 
** Conversion factors established in endocrinology were used; prednisone/prednisolone dose was 
multiplied by 5, and dexamethasone dose was multiplied by 80.10 This dexamethasone conversion was 

























Table 5. Secondary outcomes and vital signs at baseline and change at 24 weeks and then at 2 years in 
extension study. Mean (SD) 
Outcome MR-HC Group 
Baseline & change at 24 weeks 
Standard Glucocorticoid 
Group Baseline & change at 
24 weeks 
Extension Study  
MR-HC  





N=61 N=61 N=50 
Baseline Change Baseline Change Baseline† Change 
Weight (kg) 75.5 (18.5) 0.87 (3.7) 74.6 (13.2) 1.0 (2.7) 75.6 (16.1) -0.28 (4.8) 
Body mass index (kg/m
2
) 28.5 (6.4) 0.3 (1.5) 27.7 (4.3) 0.4 (1.0) 28.8 (5.7) -0.08 (2.0) 
Waist circumference (cm) 90.9 (16.3) 0.2 (5.4) 90.5 (11.8) 1.0 (5.6) 91.5 (14.8) 0.69(5.7) 
Systolic blood pressure 
(mmHg)  
120.9 (13.6) -1.8 (11.4) 120.2 (14.4) 0.5 (11.2) 120.4 (13.9) -3.1 (10.4) 
Diastolic blood pressure 
(mmHg)  
71.1 (10.6) -0.5 (9.2) 70.6 (11.0) 0.2 (9.2) 70.6 (10.8) -0.4 (9.4) 
    
Efficacy Evaluable Set N=53 N=52 N=50 
Fat mass (kg) 29.535 (11.7) -0.575 (3.3) 26.163 (10.3) 0.445 (2.5) 27.943 (11.5) -0.718 (4.8) 
Lean mass (kg) 46.975 (9.3) 0.640 (2.3) 45.468 (9.1) 0.234 (1.4) 45.819 (9.3) -0.079 (3.4) 
Bone mineral density 
(g/cm2) 
1.126 (0.1) -0.001 (0.0) 1.111 (0.1) -0.008 (0.0) 1.094 (0.092) 0.001 (0.04) 
C-terminal cross-linked 
telopeptide (ng/L) 
570 (257) 9.3 (161) 590 (260) -23.3 (120) 540.1 (252) -52.3(176) 
Fasting osteocalcin ug/L 19.93 (8.4) -0.6 (8.1) 21.51 (10.0) -2.1 (6.3) 19.49 (7.9) 4.4 (8.2) 




















Fasting glucose (mg/dl) 92.1 (8.5) 9.9 (10.2) 90.1 (9.9) 1.8 (8.8) 91.7 (7.8) 2.6 (9.8) 
Fasting insulin mIU/L 12.6 (6.3) 1.9 (6.8) 11.7 (5.6) 3.0 (7.4) 13.0 (5.9) -2.1 (6.3) 
HOMA-IR 2.894 (1.6) 0.914 (2.1) 2.59 (1.3) 0.77 (1.8) - - 
HbA1c (%) 5.16 (0.28) 0.02 (0.26) 5.18 (0.43) -0.02 (0.28) 5.17 (0.31) 0.12 (0.23) 
Plasma Renin Activity 
(ng/ml/hour) 
3.5 (2.5) -1.0 (2.4) 2.9 (2.4) 0.4 (2.5) 3.2 (3.5) -0.2 (0.9) 
Total Testosterone 
women (ng/dl) 
33 (33.4) -21 (127.8) 32 (52.9) -9 (30.4) 147 (263.8) -13 (63.4) 
Total Testosterone men 
(ng/dl) 
453 (320.9) -26 (284.1) 481 (142.6) -36 (135.8) 271 (305.9) 
 
77 (177.1) 





















Table 6. Quality of life assessments at 24 weeks (phase III study) and then at 12 and 18 months 
(extension study). Values are mean (SD).  
Parameter Phase III Study Safety Extension Study 








SF-36 Absolute Change from Baseline by domain
+ 
T-score: bodily pain* N/A N/A N/A N/A 
T-score: general 
health perceptions 
0.79 (7.54) -1.88 (5.97) 1.43 (8.76) 2.11 (5.66) 
T-score: mental 
health 
0.86 (7.32) 0.35 (7.81) 1.49 (9.44) 1.33 (6.89) 
T-score: physical 
functioning 
1.16 (6.43) -0.52 (4.27) 0.41 (4.38) 0.28 (4.25) 
T-score: role 
emotional 
0.99 (9.95) -0.34 (9.21) 1.38 (11.65) 0.48 (8.50) 
T-score: role physical 1.91 (8.33) 0.50 (6.68) 1.42 (7.53) 0.81 (9.24) 
T-score: social 
functioning 
2.18 (9.25) 0.87 (6.86) 2.54 (9.00) 0.89 (8.95) 
T-score: vitality 0.79 (9.45) 0.92 (6.10) 2.15 (8.44) 2.56 (6.80) 
Global Fatigue Index absolute change in score from baseline 
GFI score derived 
from MAF 
-0.74 (11.1) -0.26 (7.8) -1.93 (10.1) -2.31 (10.6) 
EQ-5D Summary changes from baseline 
EQ-5D VAS Score -1.3 (13.67) -1.2 (12.62) 2.7 (17.74) 2.3 (12.33) 
EQ-5D-5L Index Score 0.02 (0.12) 0.02 (0.14) -0.01 (0.17) -0.01 (0.14) 
N=number of evaluable participants; SD=standard deviation; SF-36=Medical Outcome Short Form Health 
Survey Form 36 (Subject Questionnaire). GFI=Global Fatigue Index; MAF=multidimensional assessment 
of fatigue; EQ-5D = Standardised Health Questionnaire (5L = 5-Level); VAS = Visual Analogue Scale; GFI 
scores from 1 (no fatigue) to 50 (severe fatigue). 
+Baseline is defined as start of study in phase III study and pre-MR-HC initiation baseline in safety 
extension study. 
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